secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0001493152-24-040679
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity appoints J. Michael Edwards as CFO; $300k salary, $50k bonus, 100k RSUs
--------------------------------------------------------------------------------

- J. Michael Edwards appointed CFO effective Nov 5, 2024; annual base salary of $300,000.
- Signing bonus: $50,000 cash and restricted stock award of 100,000 shares vesting 25% immediately, then over 3 years.
- Edwards previously served as CFO from 2014-2023, oversaw 2022 IPO, and has been interim CFO since Sept 2024.
- Employment agreement has one-year initial term, auto-renews annually; he reports to CEO Maria Zannes.
- Company highlights Edwards' experience for commercialization of CyPath Lung, a noninvasive lung cancer test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315224040679/0001493152-24-040679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315224040679/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-040679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer